Ads
related to: list of p450 inhibitors for prostate cancer patients- Physician Resources
Download The Patient Brochure &
Other Helpful Resources Here.
- Dosing & Administration
Learn About Dosing Considerations
For This Targeted Treatment.
- Efficacy Information
Physicians, See How A Targeted
Treatment May Help Your Patients.
- Access Information
Find Resources For Your Patients
With Advanced Prostate Cancer.
- Physician Resources
Search results
Results From The WOW.Com Content Network
"INHIBITORS, INDUCERS AND SUBSTRATES OF CYTOCHROME P450 ISOZYMES". "The Life Raft Group: Long List of Inhibitors and Inducers of CYP3A4 and CYP2D6". "DRUGBANK Online: Cytochrome P-450 Enzyme Inhibitors". "MEDICATIONS METABOLIZED BY CYTOCHROME P450 3A4" (PDF)
Seviteronel (VT-464) is a novel CYP17A1 inhibitor which is aimed to avoid co-administration of glucocorticoid therapy. [32] In the 2010s, it underwent various phases of clinical studies and preclinical models as a drug against prostate cancer or breast cancer. [33] [34]
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...
Relative to enzalutamide and apalutamide, shows greater efficacy as an AR antagonist, improved activity against mutated AR variants in prostate cancer, little or no inhibition or induction of cytochrome P450 enzymes, and little or no central nervous system distribution.
Cytochrome P450 inhibitors is a category of agents that inhibit Cytochrome P450. Subcategories. This category has the following 8 subcategories, out of 8 total. A.
Proadifen (SKF-525A) is a non-selective inhibitor of cytochrome P450 enzymes, preventing some types of drug metabolism. [1] It is also an inhibitor of neuronal nitric oxide synthase (NOS), CYP-dependent (cytochrome P450-dependent) arachidonate metabolism, transmembrane calcium influx, and platelet thromboxane synthesis.
Ads
related to: list of p450 inhibitors for prostate cancer patients